Biotech entity
HC Wainwright is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2.3 original sources on average, compared with 3.8 for the broader beat in this window.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
HC Wainwright is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2.3 original sources on average, compared with 3.8 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.1. That works out to roughly 0.5 stories per week across a 42-day span. This profile follows 3 Biotech stories mentioning Leerink Partners across the period from July 6, 2026 to August 16, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 230 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Leerink Partners. Shared-story counts are live from our verified record — not editorial picks.
Earnings release
Replimune Group reported ($0.72) EPS, missing the ($0.69) Zacks consensus by $0.03. Stock opened at $14.97, down $0.22.
Insider sales
CEO Sushil Patel sold 39,341 shares at $12.97 and insider Konstantinos Xynos sold 11,447 shares at $12.97, both to cover tax withholding obligations.
Wedbush upgrade
Wedbush upgraded Replimune Group from neutral to outperform and set a $12.00 price target.
Leerink upgrade
Leerink Partners upgraded Replimune Group from market perform to outperform and raised its price target from $11.00 to $17.00.
BMO upgrade
BMO Capital Markets raised Replimune Group from underperform to outperform with a $16.00 price target.
Wall Street Zen upgrade
Wall Street Zen upgraded Replimune Group from strong sell to sell.
Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Source: tickerreport.com · themarketsdaily.com
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Source: Zolmax · Markets Daily
Leerink Partners is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
